While most people with COVID-19 exhibit mild symptoms, approximately one in five develop severe pneumonia.1 Of severe COVID-19 patients, approximately 5% develop a systemic dysregulated cytokine response.1,2 This extreme immune response, called cytokine storm syndrome (CSS), is associated with severe COVID-19 disease and can cause widescale cellular and organ tissue damage.
The use of inflammation, tissue and organ damage biomarkers can help clinicians understand the severity of the disease and implement timely interventions for COVID-19 patients at risk for CSS.
Siemens Healthineers has a robust menu of inflammatory markers (including a key marker, IL-6†) and other lab tests to assess tissue and organ damage.
AACC webinar: Cytokine Storm Syndrome and COVID-19
Dr. Randy Cron discusses criteria for identifying cytokine storm syndrome (CSS) in patients, complications, and available potential treatments, which include glucocorticoids but also targeted therapies that dampen pro-inflammatory cytokines such as interleukin-1 (IL-1) and IL-6.
Randy Cron, MD, PhD
University of Alabama at Birmingham
Article in Medical Lab Observer (MLO): COVID-19 and Cytokine Storm Syndrome
The authors cover the cause and symptoms of COVID-19 and how severe cases can relate to cytokine storm syndrome (CSS). Also discussed is IL-6† as a CSS biomarker and its potential predictive value for COVID-19 severity.
Educational presentation: COVID-19 and Cytokine Storm Syndrome
This video reviews a variety of COVID-19 and cytokine storm syndrome topics, including immune response to the SARS-CoV-2 virus from normal to extreme (CSS), the role of laboratory testing in detecting tissue damage caused by CSS, and how interleukin-6 (IL-6)† potentially relates to COVID-19 severity.
H. Roma Levy, MS, Medical Writer
†Products are not FDA cleared/approved for sale in the U.S.
1Siddiqi HK, et al. J Heart Lung Transplant. 2020. https://doi.org/10.1016/j.healun.2020.03.012.
2Zhou Y, et al. National Science Review. 2020. DOI: 10.1093/nsr/nwaa041.
3Qin C, et al. Clin Infect Dis. 2020. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa248/5803306.
4Del Valle, Kim-Schulze, Huang, et al. https://doi.org/10.1101/2020.05.28.20115758.
5Zhou F, et al. The Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)30566-3.
6https://www.ifcc.org/ifcc-news/2020-03-26-ifcc-information-guide-on-covid-19/. (Accessed July 23, 2020).
The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.